News & Events
EVIDENT – A Success Story
A recent article published by the European Commission announces the EVIDENT project as a “success story” and a major contribution to eradicating Ebola. The article published by the Directorate-General for Research & Innovation refers to the EVIDENT publication in the Journal Nature on 17 June 2015. This international study showed that the Ebola virus has mutated at a lower rate than feared...
EVIDENT: current activities
The EVIDENT teams continues to gather first-hand information on immune signatures of Ebola virus disease patients in the field. With participation of BNITM, INMI, PHE, and volunteers from Hannover TWINCORE and Hannover Medical School, we are investigating immune-based correlates of survival including T cell responses, NK and gamma-delta T cell immunity and the kinetics of infection in...
Ebola Conference "Ebola and Other Filoviruses", 6-10 September 2015, Mozambique
From 6-10 September 2015 the Ebola Conference "Ebola and Other Filoviruses" will take place at Praia do Tofo, Inhambane, Mozambique. Stephan Becker of Marburg University (Germany) and partner in the EVIDENT consortium will speak at this event. The conference is organized by Professor Rolf Hilgenfeld (University of Lübeck, Germany), in collaboration with the Instituto Nacional de...
EVIDENT publication in journal Nature widely disseminated across Europe
The EVIDENT paper published in the journal Nature on 17 June 2015 was widely disseminated across Europe. Please see below a few selected links referring to the EVIDENT publication in Nature: Study finds Ebola virus mutated slower than first thoughtThe Ebola virus that devastated parts of West Africa over the past year did not mutate at a faster rate than in previous outbreaks, according to an...
EVIDENT publication in the Journal Nature
On 17 June 2015 recent results from the EVIDENT project were published in the Journal Nature. The international study showed how the Ebola virus mutated and spread during the outbreak in West Africa. The international team used blood samples from Ebola infected patients collected over a 1 year period by the European Mobile Laboratory (EMLab), which was the first rapid response diagnostics unit...
EBOV sequences generated with MinION technology in real-time in Guinea
The EVIDENT consortium is releasing EBOV sequences generated with MinION technology in real-time in Guinea to support the public health response as well as the development and evaluation of EVD vaccines, therapeutics, and diagnostics.
The EVIDENT consortium is releasing EBOV sequences to support the public health response as well as the development and evaluation of EVD vaccines, therapeutics, and diagnostics.
EVIDENT: activities and timeline
The first EVIDENT team arrived in Guinea in December 2014. Since then, a substantial amount of laboratory capacity has been built at Donka Hospital in Conakry which as of now, includes multiparameter flow cytometry, class III cabinet ('glovebox'), ELISPOT, and next generation sequencing (MinION). In addition, in a second laboratory in Guéckédou, EVIDENT researchers have performed the first ever...